Skip to main content
SpringerLink
Log in

Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The purpose of this trial was to evaluate the effects of fluvastatin on the lipid profile and on renal function, as measured by creatinine clearance, in dyslipidemic patients with chronic renal failure. In this 8-month prospective, open-label, randomized, parallel-group trial, 130 patients (70 men and 60 women), after a 2-month washout period following previous lipid-lowering treatments, were randomly assigned to fluvastatin XL 80 mg given once daily (80 patients) or to standard treatment (50 patients). Mean total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride values after 3 and 6 months of treatment with fluvastatin showed statistically significant improvement compared with standard treatment. Improved renal function, as measured by creatinine clearance, was observed at the end of the 6-month treatment period in approximately 65% of patients treated with fluvastatin. The increase in creatinine clearance consistently reached 10% to 15% of baseline values. A statistically significant reduction in C-reactive protein (CRP) over baseline values was observed in approximately 75% of patients treated with fluvastatin. Furthermore, mean values of CRP for the fluvastatin standard treatment groups, respectively, were 6.78 and 10.19 at 3 months and 4.47 and 11 at 6 months. Both treatments were well tolerated. No major adverse events were noted. Results of this study suggest that fluvastatin treatment in patients with chronic renal failure is effective in improving the lipid profile, and it demonstrates good safety and tolerability. Furthermore, fluvastatin may contribute to improved nephroprotection in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease.N Engl J Med. 1990;322:700–707.

    Article  Google Scholar 

  2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies.Circulation. 1989;79:8–15.

    PubMed  CAS  Google Scholar 

  3. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease.Am J Cardiol. 1995;76:69C-77C.

    Article  PubMed  CAS  Google Scholar 

  4. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.Circulation. 1999;99:736–743.

    PubMed  CAS  Google Scholar 

  5. Sahadevan M, Kasiske BL. Hyperlipidemia in kidney disease: causes and consequences.Curr Opin Nephrol Hypertens. 2002;11:323–329.

    Article  PubMed  Google Scholar 

  6. Lintott CJ, Scott RS, Bremer JM, Shand BI. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.Am J Cardiol. 1995;76:97A-101A.

    Article  PubMed  CAS  Google Scholar 

  7. Keane WF, Brenner BM, Mazzu A, et al. The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo controlled trial in patients with ESRD.Am J Kidney Dis. 2001;37:S48-S53.

    PubMed  CAS  Google Scholar 

  8. Attman PO, Sameulsson O, Alaupovic P. Lipoprotein metabolism and renal failure.Am J Kidney Dis. 1993;21:573–592.

    PubMed  CAS  Google Scholar 

  9. Attman PO, Alaupovic P, Sameulsson O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease.Kidney Int. 1999;56(suppl 71):S14-S17.

    Article  Google Scholar 

  10. Sica DA, Gehr TWB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.Curr Opin Nephrol Hypertens. 2002; 11:123–133.

    Article  PubMed  Google Scholar 

  11. Samuelsson O, Attman PO, Knight-Gibson C, et al. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.Am J Kid Dis. 2002;39:67–75.

    PubMed  CAS  Google Scholar 

  12. Gheith OA, Sobh MA, Mohamad K-S, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome.Nephron. 2002;91:612–619.

    Article  PubMed  CAS  Google Scholar 

  13. Locsey L, Asztalos L, Kincses Z, Balazs G. Fluavastatin (Lescol) treatment of hyperlipidemia in patients with renal transplants.Int Urol Nephrol. 1997;29:95–106.

    Article  PubMed  CAS  Google Scholar 

  14. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin.Clin Pharmacol. 2001;40:263–281.

    Article  CAS  Google Scholar 

  15. Appel-Dingemanse S, Smith T, Merz M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome.J Clin Pharmacol. 2002;42:312–318.

    Article  PubMed  CAS  Google Scholar 

  16. Ballantyne CM, Pazzucconi F, Pintò X, et al. Efficacy and tolerability of fluvastatin extendedrelease delivery system: a pooled analysis.Clin Ther. 2001;23:177–192.

    Article  PubMed  CAS  Google Scholar 

  17. Corsini A, Jacobson TA, Ballantyne CM. Fluvastatin: clinical and safety profile.Drugs. 2004; 64:1305–1323.

    Article  PubMed  CAS  Google Scholar 

  18. Tanaka M, Itoh K, Matsushita K, et al. Effects of fluvastatin on plasma lipid abnormalities in hemodialysis patients with chronic renal failure.Nippon Jinzo Gakkai Shi. 2002;44:402–408.

    PubMed  Google Scholar 

  19. Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and fluvastatin in renal transplant recipients.Am J Transplant. 2001;1:382–386.

    Article  PubMed  CAS  Google Scholar 

  20. Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators, Cardiovascular Risk Extended Evaluation in Dialysis Patients.J Hypertens. 2000;18:1207–1213.

    Article  PubMed  CAS  Google Scholar 

  21. Tsirpanlis G, Boufidou F, Manganas S, et al. Treatment with fluvastatin rapidly modulates, via different pathways and in dependence on the baseline level, inflammation in hemodialysis patients.Blood Purification. 2004;22:518–524.

    Article  PubMed  CAS  Google Scholar 

  22. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects.Arterioscler Thromb Vasc Biol. 2001;21:1962–1968.

    Article  PubMed  CAS  Google Scholar 

  23. Blankenberg S, Rupprecht HJ, Bickel C, et al. Statins and inflammatory markers. The role of inflammation and infection in acute coronary.Curr Atheroscler Rep. 2002;4:42–47.

    Article  Google Scholar 

  24. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.Kidney Int. 1999;55:648–658.

    Article  PubMed  CAS  Google Scholar 

  25. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.J Am Soc Nephrol. 2002;13:490–496.

    Article  PubMed  CAS  Google Scholar 

  26. Alzali B, Bakri RS, Bharma-Ariza P, et al. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.J Nephrol. 2003;16:540–545.

    Google Scholar 

  27. Chi DS, Jin FX, Yang SG, Su YW, Zhang Y, Liu YL. Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia.Di Yi Jun Yi Da Xue Xue Bao. 2002;22:1109–1111.

    PubMed  Google Scholar 

  28. Van Haelst PL, van Doormaal JJ, May GF, et al. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein.Eur J Intern Med. 2001;12:503–509.

    Article  PubMed  Google Scholar 

  29. Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialiysis patients with type 2 diabetes mellitus.Nephrol Dial Transplant. 2002;17:1513–1517.

    Article  PubMed  CAS  Google Scholar 

  30. Baigent C, Landray M, Warren M. Statin therapy in kidney disease populations. Potential benefits beyond lipid lowering and need for clinical trials.Curr Opin Nephrol Hypertens. 2004; 13:601–605.

    Article  PubMed  CAS  Google Scholar 

  31. Holdaas H, Fellström B, Jardine AG, et al, on behalf of the ALERT Study Group. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.Nephrol Dial Transplant. 2005;20:974–980.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Dialysis, S. Giovanni Evangelista Hospital, 0001 9, Tivoli, Rome, Italy

    L. Di Lullo MD, R. Addesse MD, C. Comegna MD, G. Firmi MD, C. Galderisi MD, G. R. Iannacci MD & P. Polito MD

Authors
  1. L. Di Lullo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Addesse MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Comegna MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Firmi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Galderisi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. R. Iannacci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Polito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Lullo, L., Addesse, R., Comegna, C. et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Adv Therapy 22, 601–612 (2005). https://doi.org/10.1007/BF02849954

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02849954

Keywords

Search

Navigation